AUTHOR AND EDITOR INFORMATION

Section 1 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

INTRODUCTION

Section 2 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

Background

Anytime subretinal fluid accumulates in the space between the neurosensory retina and the underlying retinal pigment epithelium (RPE), a retinal detachment occurs. Depending on the mechanism of subretinal fluid accumulation, retinal detachments traditionally have been classified into rhegmatogenous, tractional, and exudative.

A tractional retinal detachment (TRD) is the second most common type of retinal detachment after a rhegmatogenous retinal detachment (RRD).

Pathophysiology

In TRD secondary to proliferative vitreoretinopathy (PVR) and penetrating trauma, contractile vitreoretinal, epiretinal, intraretinal (very rarely), or subretinal membranes pull the neurosensory retina away from the RPE. Microscopic examinations of these membranes have revealed their cellular composition. RPE cells, glial cells, fibrocytes, macrophages, and collagen fibrils are important components of these membranes. RPE cells are the major players in these membranes. They gain access to the vitreous cavity during retinal break formation. It has been shown that the amount of RPE cells in the vitreous cavity correlates with the size of the retinal breaks. The larger the break, the larger the amount of RPE cells intravitreally.

In addition, RPE cells also may be dispersed into the vitreous cavity by excessive cryotherapy, cryotherapy on bare RPE, and scleral indentation following cryotherapy. Once in the vitreous cavity, the RPE cells undergo morphological changes where they attain fibroblastlike activity, secreting growth factors that stimulate collagen and fibronectin production.

Cryotherapy also causes breakdown of the blood-ocular barrier, allowing serum to enter the eye. Serum components fibronectin and platelet-derived growth factor (PDGF) are strong chemoattractants for other RPE cells, astrocytes, and fibrocytes. Thus, one can understand the risk that vitreous hemorrhage poses in the chances of periretinal membrane formation. Once collagen sheets form, the individual cells pull on them, leading to TRD.

TRD may occur in a number of ocular pathologic conditions, such as proliferative diabetic retinopathy (PDR), sickling hemoglobinopathies, retinal venous obstructions, and retinopathy of prematurity (ROP), that are characterized by progressive retinal ischemia. Progressive retinal ischemia leads to secretion of growth factors, especially vascular endothelial growth factor (VEGF). Neovascularization ensues, and the vitreous serves as a scaffold where strong vitreoretinal adhesions develop. With time, as the vitreous starts pulling away, a mechanical separation of the neurosensory retina from the underlying RPE occurs.

Frequency

United States

PVR is responsible for most failures of retinal reattachment surgery. It occurs in about 7% of eyes after retinal reattachment surgery. In 1 year, approximately 1600 new cases of PVR are seen.

Approximately 500 cases of blindness secondary to ROP are reported per year in the United States.

Mortality/Morbidity

• Recent series have reported that the anatomical success rates of PVR are about 75-90%. However, the functional results are not that good since only about 40-50% of eyes attain 20/400 or better visual acuity.  
• ROP complicated by TRD is the leading cause of childhood blindness.
• Diabetic retinopathy is the leading cause of blindness in the working age group. In the 1960s, prior to the advent of laser photocoagulation, up to 50% of patients with PDR were legally blind. With new techniques, currently only 5% of patients with PDR progress to legal blindness.

Race

TRD related to sickle cell disease occurs mainly in blacks.

Sex

No studies exist that specifically refer to the incidence of TRD according to gender. However, it is well known that men are more susceptible to penetrating trauma than women.

Age

The incidence of TRD according to age depends on the cause.

CLINICAL

Section 3 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

History

• Vitreoretinal traction develops insidiously in most cases.
• The visual field defect progresses slowly and may become stationary for months or years.
• If the macula becomes involved, the patient will experience a drop in vision.

Physical

• The detachment has a concave configuration.
• The subretinal fluid is shallower than in RRD and often does not extend to the ora serrata.
• The highest elevation of the retina occurs in sites of vitreoretinal traction.
• Retinal mobility is severely reduced, and shifting fluid is absent.

Causes

• PDR
• ROP
• Penetrating trauma
• Proliferative sickle retinopathy
• PVR
• Retinal venous occlusions

DIFFERENTIALS

Section 4 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

Other Problems to be Considered

Toxocara
Penetrating trauma

WORKUP

Section 5 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

Lab Studies

• The diagnosis of a TRD is made clinically. Further laboratory workup is unnecessary.

Imaging Studies

• In eyes with vitreous hemorrhage, a B-scan ultrasound is a useful adjunct to evaluate the presence or absence of retinal detachment.

Histologic Findings

The same findings as those found in RRD (see Retinal Detachment, Rhegmatogenous), that is, photoreceptor outer segment loss in the acute cases. Following successful retinal reattachment, regeneration of the outer segments may occur. In chronic detachments, atrophy of the entire photoreceptor layer, cystic degeneration, macrocyst formation, demarcation lines, and even rubeosis iridis may be seen.

In addition, TRDs have periretinal proliferation. Light and electron microscopy have revealed the composition of the periretinal membranes. These are composed of RPE cells, astrocytes, fibrocytes, monocytes, and collagen fibrils.

TREATMENT

Section 6 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

Medical Care

Currently, no role exists for medical care in the treatment of TRD.

Surgical Care

Depending on the underlying cause and extent of the TRD, surgical intervention is offered to patients. For instance, a patient with TRD secondary to PDR that does not threaten the macula probably can be monitored closely. The main surgical goal in all these cases is to relieve vitreoretinal traction. Traction may be relieved with scleral buckling techniques and/or with vitrectomy.

In certain cases, combined RRD and TRD may be present. Usually, the retina becomes detached from the vitreoretinal traction. With further traction, small breaks may occur causing a combined TRD-RRD. In these cases, the surgical goal is to identify all the breaks and to close them in addition to the relief of vitreoretinal traction.

• In TRD secondary to PVR, usually a broad circumferential element, such as a 287 buckle, is placed. A decision is made whether the crystalline lens needs to be sacrificed. A complete vitrectomy follows. Inside-out (posterior to anterior) forceps (not pick) membrane peeling is the preferred dissection method with or without perfluorocarbon liquid injection. Perfluorocarbon liquid may be injected at the surgeon's discretion to stabilize the posterior retina. If residual traction remains, subretinal membranes may need to be excised if causing traction. If necessary, a relaxing retinectomy is created. A fluid-air exchange is performed. Endophotocoagulation is followed by either air-silicone oil exchange or air-gas exchange. If perfluorocarbon liquids are not used, the dissection starts anteriorly and proceeds posteriorly.
• A randomized controlled clinical trial of a perioperative infusion of 5-fluorouracil and low molecular weight heparin was not able to demonstrate a better surgical outcome in eyes with established PVR.
• In TRD secondary to PDR, several surgical techniques have been developed. A scleral buckle usually is not used unless anterior breaks are present.
• • A central vitrectomy is performed with the vitrector clearing the axial opacities and the cortical vitreous gel. A large opening is created in the posterior hyaloid until vitreoretinal adhesions are encountered. Segmentation and/or delamination of these adhesions (as described by Charles) are used for virtually all diabetic TRD.
  • Delamination refers to the separation of the retina from the extraretinal proliferation. This dissection proceeds from posterior to anterior. Fibrovascular tissue often bridge separate retinal zones. Segmentation refers to cutting of the fibrovascular tissue bridge into small separate islands of tissue.
  • Care must be given to create as few iatrogenic breaks as possible. If breaks are identified, usually fluid-air exchange with photocoagulation reattaches the retina. Breaks should be marked with diathermy, so they are identified easily in the air-filled eye. The incidence of RRD in patients who underwent vitrectomy for PDR has been reported to be 4.3%. Intraocular bleeding also must be monitored closely. Diathermy to active neovascular fronds may be necessary.
  • Other techniques include the en bloc dissection. En bloc is a name applied to outside-in delamination where the vitreous is used to pull on the epiretinal membrane. Outside-in causes more retinal breaks than inside-out, making it a dangerous maneuver.
  • Intravitreal bevacizumab has been reported as a preoperative adjunct in vitrectomy for PDR. Bevacizumab seems to reduce the bleeding associated with the segmentation and delamination of fibrovascular membranes. However, in eyes with severe ischemia, the neovascularization regresses rapidly, but the resulting fibrous scar tissue may lead to the development or progression of TRD. Therefore, caution should be exercised when injecting these eyes, and patients should be scheduled for surgery days, and not weeks, after the injection.
• The treatment of TRD secondary to ROP depends on the stage of the disease.
• • Although many vitreoretinal surgeons advocate an encircling band for stage 4A ROP, no scientific evidence is available that supports its efficacy. In stage 4B, vitrectomy is recommended. It is currently unclear if lens-sparing vitrectomy has any advantages over lensectomy.
  • For stage 5 ROP, visual and anatomical results have been disappointing, making some surgeons abandon surgery for these cases. Others have tried vitrectomy and lensectomy with or without scleral buckling. In these cases, a 2-port vitrectomy technique is recommended since the small size of the eye and orbit limits ocular manipulation if a 3-port technique is used. The use of intravitreal triamcinolone as a postoperative adjuvant might improve the rate of retinal reattachment after vitrectomy.
  • A recent case series of aggressive posterior ROP suggested that early vitrectomy with lensectomy in these cases is effective in preventing TRD.
  • Special attention must be given to avoid iatrogenic retinal breaks because of the poor prognosis associated with this complication. The goal of surgery is to obtain macular reattachment.

Consultations

Patients with TRD should be referred to an experienced vitreoretinal surgeon for further management.

MEDICATION

Section 7 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

TRDs are considered to be surgical diseases. However, experimental drugs have been used in numerous protocols to try to prevent PVR at different stages of the disease process. Among the drugs studied are heparin and its low molecular weight derivatives, corticosteroids and nonsteroidal anti-inflammatory agents, antimetabolites, and retinoic acid. Most of these agents have been shown to reduce retinal proliferation. However, such issues as drug toxicity, drug delivery, and drug duration of action remain without an ideal solution.

FOLLOW-UP

Section 8 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

Further Inpatient Care

• Most vitreoretinal procedures currently are performed in an ambulatory setting.

Further Outpatient Care

• Certain eyes that undergo vitreoretinal surgery have an intraocular gas bubble to serve as internal tamponade. Depending on the gas used and the location of the breaks, the surgeon instructs the patient to maintain a certain head position for a limited time.

In/Out Patient Meds

• Postoperative medications usually include a topical corticosteroid, a topical cycloplegic, and a topical antibiotic. The intraocular pressure is monitored and controlled accordingly.

Deterrence/Prevention

• PVR
  
  
  • Extensive cryotherapy, cryotherapy over bare RPE, and scleral depression after cryotherapy should be avoided because this will disperse RPE cells into the vitreous cavity. Cryotherapy also causes breakdown of the blood-ocular barrier, allowing serum (containing various growth factors believed to be stimulatory to the formation of PVR) to enter the eye.
  • A double-masked, prospective, randomized, placebo-controlled clinical trial reported that adjuvant therapy with 5-fluorouracil and low molecular weight heparin does not improve anatomical and visual success rates in retinal detachments with preexisting PVR. Furthermore, it is associated with worse visual outcomes in cases with macula-sparing retinal detachment.
• PDR: Patients with diabetes should be monitored closely and treated with aggressive panretinal photocoagulation when indicated.
• ROP: Screening protocols should be monitored, and patients should be treated with laser or cryotherapy as indicated.

Complications

• Retinal redetachment
• Vitreous hemorrhage
• Phthisis bulbi

Prognosis

• Visual prognosis depends on the underlying cause of TRD.
  
  
  • Anatomical success rates for retinal reattachment surgery for PVR are anywhere from 75-90% of eyes. However, visual results are poor, since only about 40-50% obtain a visual acuity of 20/400 or better.
  • The results after ROP surgery are very poor but better than the natural history (no light perception).
  • For PDR, series by Rice et al, Thompson et al, and Williams et al report 70-80% of eyes attain 5/200 or better visual acuity with 40% achieving 20/100 or better.^{1, 2, 3}

Patient Education

• Patients with diabetes must be aware that a fully dilated eye examination by a competent ophthalmologist should be performed at least once a year. Depending on the presence and degree of retinopathy, the patient may need to be seen on a more frequent basis.
• Patients should be educated about the importance of good glycemic, hypertensive, and lipemic control.

MISCELLANEOUS

Section 9 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

Medical/Legal Pitfalls

• In the cases of ROP, an extensive informed consent has to be discussed with the parents.

MULTIMEDIA

Section 10 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

Media file 1:  Patient with a central retinal vein occlusion complicated by neovascularization at the disc with subsequent tractional retinal detachment.
	View Full Size Image
Media type:  Photo

Media file 2:  This patient underwent a scleral buckle for a rhegmatogenous retinal detachment. Now, the patient presents with proliferative vitreoretinopathy with a membrane tenting up and detaching the retina.
	View Full Size Image
Media type:  Photo

Media file 3:  A patient with proliferative diabetic retinopathy complicated by a tractional retinal detachment over the supertemporal arcade.
	View Full Size Image
Media type:  Photo

REFERENCES

Section 11 of 11

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

1. Rice TA, Michels RG, Rice EF. Vitrectomy for diabetic traction retinal detachment involving the macula. Am J Ophthalmol. Jan 1983;95(1):22-33. [Medline].
2. Thompson JT, de Bustros S, Michels RG, Rice TA. Results and prognostic factors in vitrectomy for diabetic traction retinal detachment of the macula. Arch Ophthalmol. Apr 1987;105(4):497-502. [Medline].
3. Williams DF, Williams GA, Hartz A, Mieler WF, Abrams GW, Aaberg TM. Results of vitrectomy for diabetic traction retinal detachments using the en bloc excision technique. Ophthalmology. Jun 1989;96(6):752-8. [Medline].
4. Abrams GW, Williams GA. "En bloc" excision of diabetic membranes. Am J Ophthalmol. Mar 15 1987;103(3 Pt 1):302-8. [Medline].
5. Archives of Ophthalmology. Vitrectomy with silicone oil or sulfur hexafluoride gas in eyes with severe proliferative vitreoretinopathy: results of a randomized clinical trial. Silicone Study Report 1. Arch Ophthalmol. Jun 1992;110(6):770-9. [Medline].
6. Asaria RH, Kon CH, Bunce C, Charteris DG, Wong D, Khaw PT, et al. Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy: Results from a randomized, double-blind, controlled clinical trial. Ophthalmology. Jul 2001;108(7):1179-83. [Medline].
7. Asaria RH, Kon CH, Bunce C, Charteris DG, Wong D, Luthert PJ, et al. How to predict proliferative vitreoretinopathy: a prospective study. Ophthalmology. Jul 2001;108(7):1184-6. [Medline].
8. Asaria RH, Kon CH, Bunce C, Sethi CS, Limb GA, Khaw PT, et al. Silicone oil concentrates fibrogenic growth factors in the retro-oil fluid. Br J Ophthalmol. Nov 2004;88(11):1439-42. [Medline].
9. Azuma N, Ishikawa K, Hama Y, Hiraoka M, Suzuki Y, Nishina S. Early vitreous surgery for aggressive posterior retinopathy of prematurity. Am J Ophthalmol. Oct 2006;142(4):636-43. [Medline].
10. Blumenkranz M, Hernandez E, Ophir A, Norton EW. 5-fluorouracil: new applications in complicated retinal detachment for an established antimetabolite. Ophthalmology. Feb 1984;91(2):122-30. [Medline].
11. Blumenkranz MS, Hartzer MK, Hajek AS. Selection of therapeutic agents for intraocular proliferative disease. II. Differing antiproliferative activity of the fluoropyrimidines. Arch Ophthalmol. Mar 1987;105(3):396-9. [Medline].
12. Blumenkranz MS, Ophir A, Claflin AJ, Hajek A. Fluorouracil for the treatment of massive periretinal proliferation. Am J Ophthalmol. Oct 1982;94(4):458-67. [Medline].
13. Campochiaro PA, Glaser BM. Endothelial cells release a chemoattractant for retinal pigment epithelial cells in vitro. Arch Ophthalmol. Dec 1985;103(12):1876-80. [Medline].
14. Campochiaro PA, Glaser BM. Mechanisms involved in retinal pigment epithelial cell chemotaxis. Arch Ophthalmol. Feb 1986;104(2):277-80. [Medline].
15. Campochiaro PA, Glaser BM. Platelet-derived growth factor is chemotactic for human retinal pigment epithelial cells. Arch Ophthalmol. Apr 1985;103(4):576-9. [Medline].
16. Campochiaro PA, Jerdan JA, Glaser BM, Cardin A, Michels RG. Vitreous aspirates from patients with proliferative vitreoretinopathy stimulate retinal pigment epithelial cell migration. Arch Ophthalmol. Sep 1985;103(9):1403-5. [Medline].
17. Campochiaro PA, Jerdan JA, Glaser BM, Glaser BM. Serum contains chemoattractants for human retinal pigment epithelial cells. Arch Ophthalmol. Dec 1984;102(12):1830-3. [Medline].
18. Campochiaro PA, Kaden IH, Vidaurri-Leal J, Glaser BM. Cryotherapy enhances intravitreal dispersion of viable retinal pigment epithelial cells. Arch Ophthalmol. Mar 1985;103(3):434-6. [Medline].
19. Charteris DG, Aylward GW, Wong D, Groenewald C, Asaria RH, Bunce C. A randomized controlled trial of combined 5-fluorouracil and low-molecular-weight heparin in management of established proliferative vitreoretinopathy. Ophthalmology. Dec 2004;111(12):2240-5. [Medline].
20. Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy. Retina. Jul-Aug 2006;26(6):699-700. [Medline].
21. Clarkson JG, Green WR, Massof D. A histopathologic review of 168 cases of preretinal membrane. Am J Ophthalmol. Jul 1977;84(1):1-17. [Medline].
22. Cusick M, Charles MK, Agrón E, Sangiovanni JP, Ferris FL, Charles S. Anatomical and visual results of vitreoretinal surgery for stage 5 retinopathy of prematurity. Retina. Sep 2006;26(7):729-35. [Medline].
23. de Juan E Jr, Sternberg P Jr, Michels RG. Timing of vitrectomy after penetrating ocular injuries. Ophthalmology. Sep 1984;91(9):1072-4. [Medline].
24. Glaser BM, Cardin A, Biscoe B. Proliferative vitreoretinopathy. The mechanism of development of vitreoretinal traction. Ophthalmology. Apr 1987;94(4):327-32. [Medline].
25. Glaser BM, Vidaurri-Leal J, Michels RG, Campochiaro PA. Cryotherapy during surgery for giant retinal tears and intravitreal dispersion of viable retinal pigment epithelial cells. Ophthalmology. Apr 1993;100(4):466-70. [Medline].
26. Greven C, Tasman W. Scleral buckling in stages 4B and 5 retinopathy of prematurity. Ophthalmology. Jun 1990;97(6):817-20. [Medline].
27. Hsu HT, Ryan SJ. Experimental retinal detachment in the rabbit. Penetrating ocular injury with retinal laceration. Retina. Winter-Spring 1986;6(1):66-9. [Medline].
28. Iverson DA, Katsura H, Hartzer MK, Blumenkranz MS. Inhibition of intraocular fibrin formation following infusion of low- molecular-weight heparin during vitrectomy. Arch Ophthalmol. Mar 1991;109(3):405-9. [Medline].
29. Khawly JA, Saloupis P, Hatchell DL, Machemer R. Daunorubicin treatment in a refined experimental model of proliferative vitreoretinopathy. Graefes Arch Clin Exp Ophthalmol. 1991;229(5):464-7. [Medline].
30. Kirchhof B. Strategies to influence PVR development. Graefes Arch Clin Exp Ophthalmol. Aug 2004;242(8):699-703. [Medline].
31. Kirmani M, Ryan SJ. In vitro measurement of contractile force of transvitreal membranes formed after penetrating ocular injury. Arch Ophthalmol. Jan 1985;103(1):107-10. [Medline].
32. Lakhanpal RR, Fortun JA, Chan-Kai B, Holz ER. Lensectomy and vitrectomy with and without intravitreal triamcinolone acetonide for vascularly active stage 5 retinal detachments in retinopathy of prematurity. Retina. Sep 2006;26(7):736-40. [Medline].
33. Maguire AM, Trese MT. Lens-sparing vitreoretinal surgery in infants. Arch Ophthalmol. Feb 1992;110(2):284-6. [Medline].
34. Meredith TA, Kaplan HJ, Aaberg TM. Pars plana vitrectomy techniques for relief of epiretinal traction by membrane segmentation. Am J Ophthalmol. Mar 1980;89(3):408-13. [Medline].
35. Michels RG. Proliferative diabetic retinopathy: Pathophysiology of extraretinal complications and principles of vitreous surgery. Retina. 1981;1:1-17.
36. Miller B, Miller H, Patterson R, Ryan SJ. Retinal wound healing. Cellular activity at the vitreoretinal interface. Arch Ophthalmol. Feb 1986;104(2):281-5. [Medline].
37. Pastor JC, de la Rua ER, Martin F. Proliferative vitreoretinopathy: risk factors and pathobiology. Prog Retin Eye Res. Jan 2002;21(1):127-44. [Medline].
38. Quinn GE, Dobson V, Barr CC, Davis BR, Flynn JT, Palmer EA, et al. Visual acuity in infants after vitrectomy for severe retinopathy of prematurity. Ophthalmology. Jan 1991;98(1):5-13. [Medline].
39. Rachal WF, Burton TC. Changing concepts of failures after retinal detachment surgery. Arch Ophthalmol. Mar 1979;97(3):480-3. [Medline].
40. Schrey S, Krepler K, Wedrich A. Incidence of rhegmatogenous retinal detachment after vitrectomy in eyes of diabetic patients. Retina. Feb 2006;26(2):149-52. [Medline].
41. Singh AK, Michels RG, Glaser BM. Scleral indentation following cryotherapy and repeat cryotherapy enhance release of viable retinal pigment epithelial cells. Retina. Summer-Fall 1986;6(3):176-8. [Medline].
42. Stern WH, Lewis GP, Erickson PA, Guerin CJ, Anderson DH, Fisher SK, et al. Fluorouracil therapy for proliferative vitreoretinopathy after vitrectomy. Am J Ophthalmol. Jul 1983;96(1):33-42. [Medline].
43. Sun JK, Arroyo JG. Adjunctive therapies for proliferative vitreoretinopathy. Int Ophthalmol Clin. 2004;44(3):1-10. [Medline].
44. Tano Y, Sugita G, Abrams G, Machemer R. Inhibition of intraocular proliferations with intravitreal corticosteroids. Am J Ophthalmol. Jan 1980;89(1):131-6. [Medline].
45. Trese MT. Visual results and prognostic factors for vision following surgery for stage V retinopathy of prematurity. Ophthalmology. May 1986;93(5):574-9. [Medline].
46. Tseng W, Cortez RT, Ramirez G, Stinnett S, Jaffe GJ. Prevalence and risk factors for proliferative vitreoretinopathy in eyes with rhegmatogenous retinal detachment but no previous vitreoretinal surgery. Am J Ophthalmol. Jun 2004;137(6):1105-15. [Medline].
47. Ussmann JH, Lazarides E, Ryan SJ. Traction retinal detachment. A cell-mediated event. Arch Ophthalmol. May 1981;99(5):869-72. [Medline].
48. Vidaurri-Leal J, Hohman R, Glaser BM. Effect of vitreous on morphologic characteristics of retinal pigment epithelial cells. A new approach to the study of proliferative vitreoretinopathy. Arch Ophthalmol. Aug 1984;102(8):1220-3. [Medline].
49. Vidaurri-Leal JS, Glaser BM. Effect of fibrin on morphologic characteristics of retinal pigment epithelial cells. Arch Ophthalmol. Sep 1984;102(9):1376-9. [Medline].
50. Weiss JF, Belkin M. The effect of penicillamine on posttraumatic vitreous proliferation. Am J Ophthalmol. Nov 1981;92(5):625-7. [Medline].
51. Wickham L, Bunce C, Wong D, McGurn D, Charteris DG. Randomized controlled trial of combined 5-Fluorouracil and low-molecular-weight heparin in the management of unselected rhegmatogenous retinal detachments undergoing primary vitrectomy. Ophthalmology. Apr 2007;114(4):698-704. [Medline].
52. Wiedemann P, Lemmen K, Schmiedl R, Heimann K. Intraocular daunorubicin for the treatment and prophylaxis of traumatic proliferative vitreoretinopathy. Am J Ophthalmol. Jul 15 1987;104(1):10-4. [Medline].
53. Yeo JH, Sadeghi J, Campochiaro PA, Green WR, Glaser BM. Intravitreous fibronectin and platelet-derived growth factor. New model for traction retinal detachment. Arch Ophthalmol. Mar 1986;104(3):417-21. [Medline].

Article Last Updated: Aug 2, 2007